Comparison Chart CEL-SCI Corporation

Equities

Market Closed - Nyse Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
1.27 ^USD	-9.29%		-10.56%	-53.31%

05-08	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	MT
05-08	CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	CEL-SCI CORPORATION	Biopharmaceuticals	-9.29%	-10.56%	-53.31%	-50.20%	-76.74%	68.55M